Skip directly to content

Inlyta®

Inlyta®是一種二線口服標靶藥物, 專門關注內皮細胞VEGF1,2,3受體的腎細胞增殖問題1。 在本港已被關愛基⾦納入為針對⼀種病症的受資助藥物,協助有需要⼈⼠踏上治療成功之路2

 

參考資料:​

  1. Inlyta® (axitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version August 2014
  2. Safety Net. HA Drug Formulary Management.  Accessed on 8 August 2019. https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#

[PP-CPF-HKG-0070] SEP 2019

Therapeutic Area Sub Category: